PharmaFocus Today – Page 29 – media

CDC Vaccine Advisors Unanimously Vote to Transition from Broad Covid-19 Vaccine Recommendation

On Friday, September 19, 2025, CDC’s vaccine advisors came to a unanimous vote shifting away from broad recommendations for Covid-19 vaccines. According to a report from CNN, the advisors agreed on transferring its recommendation to a process known as shared clinical decision-making, which entails patients consulting a professional healthcare provider before receiving the vaccine. Requiring clinical decision-making “assumes health care and insurance,” said Dr. Demetre Daskalakis, who recently resigned as head of the CDC’s National Center for Immunization and Respiratory Diseases. Daskalakis continued to say, “We do not have universal health care in this country, and we know millions of people are losing insurance.” What was ACIP’s decision on Covid-19 vaccine recommendations? Despite the unanimous vote from CDC’s vaccine advisors, the Advisory Committee on Immunization Practices (ACIP) was split on its recommendation to require prescriptions for Covid-19 vaccines. According to a report from CNN, the vote ended in even split ...
- Source: drugdu
- 125
- September 25, 2025
Fish Oil May Raise or Lower Colon Cancer Risk, Depending on Your Genes

WEDNESDAY, Sept. 24, 2025 (HealthDay News) — About 19 million U.S. adults take fish oil supplements, often to protect against chronic diseases. But new research suggests their ability to lower colon cancer risk may depend on a single gene. Scientists at the University of Michigan and the University of Texas MD Anderson Cancer Center found that the gene 15-lipoxygenase-1 (ALOX15) is critical for omega-3 fatty acids in fish oil (EPA and DHA) to fight colon cancer. The study — recently published in the journal Cellular and Molecular Gastroenterology and Hepatology — showed that without ALOX15, fish oil could actually raise the risk of colon tumors in mice. “Not all fish oil supplements are the same,” senior researcher Imad Shureiqi, professor of internal medicine at the University of Michigan Rogel Cancer Center in Ann Arbor, said in a news release. “It is also important to ask whether the person who is ...
- Source: drugdu
- 124
- September 25, 2025
Obtained drug clinical trial approval notice

On September 24, Jiudian PharmaceuticalThe company announced in the evening that it recently received the “Notice of Approval for Drug Clinical Trial” from the National Medical Products Administration (NMPA). Clinical trials will commence after completing relevant preparatory work. The relevant information is as follows: JIZM01 is indicated for closed soft tissue contusions and joint sprains, while JIZM02 is indicated for periarthritis of the shoulder. Following review, approval has been granted for clinical trials in accordance with the Drug Administration Law of the People’s Republic of China and relevant regulations. https://finance.eastmoney.com/a/202509243522589468.html
- Source: drugdu
- 103
- September 25, 2025
51.9 billion, Pfizer increases investment in GLP-1?

On September 22, according to multiple media reports, global pharmaceutical giant Pfizer is close to completing a major acquisition, and will acquire Metsera, a developer of ultra-long-acting weight loss drugs, for US$7.3 billion (approximately RMB 51.9 billion). This may become one of the important acquisition events in the pharmaceutical field this year. Pfizer plans to pay $47.50 per Metsera share in cash, with an additional $22.50 per share payable if Metsera meets certain performance targets, valuing Metsera at up to $7.3 billion. The acquisition could be announced as early as September 22. Metsera specializes in the research and development of weight loss drugs. Its lead drug, MET-097i, is considered an improvement over the current generation of GLP-1 drugs and is expected to revolutionize the weight loss drug market. Obesity, a chronic disease with a steadily increasing incidence in recent years, presents a significant market demand, while existing treatment options are ...
- Source: drugdu
- 115
- September 25, 2025
Gan & Lee Pharmaceuticals signed a supply framework agreement worth over 3 billion yuan with a local Brazilian company

Shanghai Securities News China SecuritiesGanli PharmaceuticalsOn September 24th, the company announced that it had signed a Technology Transfer and Supply Agreement with Fundao Oswaldo Cruz-Bio-Manguinhos (FZ), a public laboratory under the Brazilian Ministry of Health, and BIOMM SA (BIOMM), a Brazilian biopharmaceutical company. The company also signed a Supply Framework Agreement with BIOMM. According to the announcement, the contract value of the Supply Framework Agreement is expected to be no less than RMB 3 billion, with a term of 10 years. This collaboration is centered around Brazil’s Production Development Partnership Program (Parcerias para oDesenvolvimento Produtivo, or PDP). A key initiative of Brazil’s national public health system, the program aims to promote local pharmaceutical production through technology transfer from multinational pharmaceutical companies, ensuring a long-term, stable supply of essential medicines in Brazil. As early as 2014, Gan & Lee Pharmaceuticals and BIOMM established a comprehensive and in-depth partnership, introducing their superior ...
- Source: drugdu
- 110
- September 25, 2025
Ruikang Trastuzumab’s overseas sales to Indian companies exceed US$1 billion

Hengrui Medicine (600276.SH) this year’s innovative drugsGoing overseas may break the record – today it announced that Ruikang Trastuzumab has been exported to an Indian multinational pharmaceutical company, with the total BD transaction amount exceeding US$1 billion. This is Hengrui Medicine ‘s fifth BD transaction this year, and the cumulative down payment for BD transactions reached this year has exceeded US$800 million. Hengrui Medicine announced today that it has signed a licensing agreement with Glenmark Specialty SA, a subsidiary of India’s Glenmark Pharmaceuticals (hereinafter referred to as GP), to license the development and commercialization rights of its independently developed antibody-drug conjugate (ADC) Ruikang Trastuzumab (SHR-A1811) project to the other party on a paid basis. The authorized area is the global market except Greater China, the United States, Canada, Europe, Japan, Russia and Central Asia. Under the agreement, Hengrui will receive an upfront payment of US$18 million and will be eligible ...
- Source: drugdu
- 135
- September 25, 2025
mRNA cancer vaccines will be put into clinical patient trials in the near future

Since the pandemic, scientists have been working hard to apply mRNA technology to cancer treatment, and now there are new progresses. According to the latest news on Tuesday, Ginzburg, director of the Russian “Gamaleya” National Research Center for Epidemiology and Microbiology, said at a roundtable that Russia’s domestically produced individualized cancer vaccine is ready and will be used to treat the first Russian patients after regulatory approval. “All documents were submitted to the Ministry of Health some time ago, and we hope that in the near future, the Herzen Institute, the Blochin Institute and our institute will be able to obtain permission to produce the first individualized vaccines (for melanoma),” Ginzburg said. Accordingly, the patient population has been formed, their individualized genetic data has been identified, and we are ready to start treating them in a month to a month and a half through joint efforts. ” As an experimental ...
- Source: drugdu
- 119
- September 24, 2025
Semaglutide China’s patent is about to expire, and Novo Nordisk is accelerating the launch of oral weight loss drugs

In 2026, the Danish pharmaceutical giantNovo NordiskThestar weight loss drug semaglutide core molecule patent is about to expire in China, at which time the drug will face a lot of competition from Chinese generics. In this context,Novo NordiskIt is actively promoting the global launch process of oral semaglutide weight loss drugs. recentlyNovo NordiskA recent Phase 3 clinical trial published in the New England Journal of Medicine (NEJM) evaluated the efficacy and safety of an investigational once-daily oral semaglutide tablet (25mg tablet). The results showed that at 64 weeks of medication, the patients in the oral semaglutide tablets 25mg group achieved an average weight loss of 16.6%, and more than one-third (34.4%) of the patients achieved a weight loss of 20% or more, and the weight loss effect was comparable to that of semaglutide injection. Novo Nordisk has submitted a new drug application to the US FDA in February this year ...
- Source: drugdu
- 313
- September 24, 2025
The company’s nine-valent HPV vaccine phase III clinical research is ongoing

Watson Bio（300142. SZ) said on the investor interactive platform on September 24 that the relevant work of the company’s nine-valent HPV vaccine phase III clinical research is continuing, and if there is substantial and phased progress in the research and development of the company’s developing vaccine, the company will disclose it in a timely manner, and please pay attention to the relevant information disclosed by the company for the follow-up progress. https://finance.eastmoney.com/a/202509243522306220.html
- Source: drugdu
- 145
- September 24, 2025
Lincomycin Hydrochloride Injection Passes Generic Drug Consistency Evaluation

On September 23rd, Tianfang Pharmaceutical, a wholly-owned subsidiary of SINOPHARM, announced that it has received notification from the National Medical Products Administration (NMPA) that Lincomycin Hydrochloride Injection has passed the generic drug quality and efficacy consistency evaluation. This drug is primarily used to treat serious infections caused by susceptible strains of Streptococcus, Pneumococcus, and Staphylococcus. Passing the consistency evaluation will provide greater support in areas such as medical insurance payment and procurement by medical institutions, helping to enhance its market competitiveness. However, there is a risk that sales may not meet expectations due to policy and market factors. https://finance.eastmoney.com/a/202509233521233113.html
- Source: drugdu
- 81
- September 24, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.